Osmofundina Concentrada (Mannitol)

Mannitol, the active ingredient in Osmofundina Concentrada, is a sugar‑alcohol osmotic diuretic presented as a concentrated solution for intravenous use. It is employed to lower intracranial and intra‑ocular pressure and to promote diuresis in patients with acute renal impairment. The formulation provides rapid osmotic effect, allowing swift fluid shift from the intracellular to the extracellular compartment, which contributes to its therapeutic action.

GNH USA supplies Osmofundina Concentrada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Mannitol acts as an osmotic agent to reduce fluid accumulation in several clinical conditions.

Cerebral edema: reduces intracranial pressure by drawing water out of brain tissue. Acute glaucoma: lowers intra‑ocular pressure through osmotic fluid shift. Acute renal failure (oliguria): promotes osmotic diuresis to increase urine output.

Mannitol may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate headache may occur. - Nausea: feeling of nausea is frequently reported. - Vomiting: occasional vomiting may follow infusion. - Electrolyte imbalance: transient changes in sodium or potassium levels.

Serious or Rare Side Effects: - Pulmonary edema: fluid accumulation in lungs can be life‑threatening. - Severe hyponatremia: marked drop in serum sodium may cause neurological symptoms. - Anaphylactic reaction: rare but possible severe allergic response. - Renal failure: worsening kidney function in susceptible patients.

When using Osmofundina Concentrada, careful clinical assessment and monitoring are essential. - Assess renal function: evaluate baseline kidney performance before administration. - Monitor electrolytes: check serum sodium and potassium during therapy. - Avoid in severe dehydration: risk of further fluid loss. - Use cautiously in heart failure: may exacerbate volume overload. - Adjust dose in elderly: age‑related renal decline may require lower amounts. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Mannitol can interact with several drug classes; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid): - Loop diuretics: combined use can cause excessive fluid loss and electrolyte disturbances. - Lithium: mannitol may increase lithium toxicity by altering renal clearance. - ACE inhibitors: risk of acute kidney injury when used together. - Antihypertensives: may lead to profound hypotension.

Moderate Interactions (Monitor Closely): - NSAIDs: can reduce the diuretic effect of mannitol. - Anticoagulants: fluid shifts may affect coagulation parameters. - Carbamazepine: may alter serum levels of both agents.